Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2.75

Health Catalyst -2.20%

Health Catalyst

HCAT

1.78

-2.20%

Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ: HCAT) with a Neutral and lowers the price target from $3.25 to $2.75.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via